CCX872: Phase Ib data

Top-line data from 41 evaluable patients with non-resectable pancreatic cancer who had >=1 post-baseline CT scan in an open-label, U.S. and Dutch Phase Ib trial showed that twice-daily 150 mg oral CCX...